Extrapolation concept at work with biosimilar: a decade of experience in oncology.
作者信息
Krendyukov Andriy, Schiestl Martin
机构信息
Sandoz Biopharmaceuticals, Hexal AG, Holzkirchen, Germany.
Sandoz GmbH, Kundl, Austria.
出版信息
ESMO Open. 2018 Feb 6;3(2):e000319. doi: 10.1136/esmoopen-2017-000319. eCollection 2018.
Abstract
摘要
相似文献
1
Extrapolation concept at work with biosimilar: a decade of experience in oncology.生物类似药的外推概念应用：肿瘤学领域十年经验
ESMO Open. 2018 Feb 6;3(2):e000319. doi: 10.1136/esmoopen-2017-000319. eCollection 2018.
2
Biosimilars in oncology: A decade of experience with granulocyte colony-stimulating factor and its implications for monoclonal antibodies.肿瘤学中的生物类似药：粒细胞集落刺激因子十年经验及其对单克隆抗体的启示
Crit Rev Oncol Hematol. 2019 Jul 23:102785. doi: 10.1016/j.critrevonc.2019.07.009.
3
Biosimilar monoclonal antibodies: the scientific basis for extrapolation.生物类似药单克隆抗体：外推法的科学依据。
Expert Opin Biol Ther. 2015;15(11):1633-46. doi: 10.1517/14712598.2015.1083552. Epub 2015 Sep 12.
4
Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.生物类似单克隆抗体：加拿大监管机构对临床相关差异评估及适应症外推的观点。
J Clin Pharmacol. 2015 Mar;55 Suppl 3:S123-32. doi: 10.1002/jcph.339. Epub 2014 Jun 26.
5
[Biosimilar drugs in oncology].[肿瘤学中的生物类似药]
Bull Cancer. 2016 Mar;103(3):294-8. doi: 10.1016/j.bulcan.2015.12.004. Epub 2016 Jan 29.
6
Safety and efficacy of biosimilars in oncology.生物类似药在肿瘤学中的安全性和疗效。
Lancet Oncol. 2016 Nov;17(11):e502-e509. doi: 10.1016/S1470-2045(16)30374-6.
7
Biosimilars: Extrapolation for oncology.生物类似药：肿瘤学的外推。
Crit Rev Oncol Hematol. 2016 Aug;104:131-7. doi: 10.1016/j.critrevonc.2016.06.002. Epub 2016 Jun 15.
8
Biosimilars and the extrapolation of indications for inflammatory conditions.生物类似药与炎症性疾病适应症的外推法
Biologics. 2017 Feb 17;11:5-11. doi: 10.2147/BTT.S124476. eCollection 2017.
9
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.在美国、欧盟、日本和加拿大的生物类似物非格司亭的监管和临床经验。
Oncologist. 2019 Apr;24(4):537-548. doi: 10.1634/theoncologist.2018-0341. Epub 2019 Mar 6.
10
From bioequivalence to biosimilars: How much do regulators dare?从生物等效性到生物类似药：监管机构究竟有多大的胆量？
Z Evid Fortbild Qual Gesundhwes. 2019 Mar;140:58-62. doi: 10.1016/j.zefq.2018.12.001. Epub 2019 Jan 6.
引用本文的文献
1
Does the introduction of an infliximab biosimilar always result in savings for hospitals? A descriptive study using real-world data.引入英夫利昔单抗生物类似药是否总能为医院节省费用？一项使用真实世界数据的描述性研究。
Health Econ Rev. 2024 Apr 29;14(1):31. doi: 10.1186/s13561-024-00507-5.
2
Consensus-Based Overarching Principles and Recommendations on the Use of Biosimilars in the Treatment of Inflammatory Arthritis in the Gulf Region.《海湾地区炎症性关节炎生物类似药治疗应用的共识性总体原则和推荐意见》。
BioDrugs. 2024 May;38(3):449-463. doi: 10.1007/s40259-023-00642-1. Epub 2024 Feb 25.
3
Biosimilars: From Production to Patient.生物类似药：从生产到患者。
J Infus Nurs. 2024;47(1):19-29. doi: 10.1097/NAN.0000000000000528.
4
The Importance of Countering Biosimilar Disparagement and Misinformation.抵制生物类似药诋毁和误导信息的重要性。
BioDrugs. 2020 Aug;34(4):407-414. doi: 10.1007/s40259-020-00433-y.
5
Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars.理解比较临床研究在肿瘤生物类似药开发中的作用。
J Clin Oncol. 2020 Apr 1;38(10):1070-1080. doi: 10.1200/JCO.19.02953. Epub 2020 Feb 14.
6
Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States.乳腺癌生物类似药：美国HER2靶向抗体综述
Ther Adv Med Oncol. 2019 Nov 14;11:1758835919887044. doi: 10.1177/1758835919887044. eCollection 2019.
本文引用的文献
1
Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.比较粒细胞集落刺激因子非格司亭和培非格司亭与其生物类似药在乳腺癌患者中的疗效和安全性：一项随机临床试验的荟萃分析。
Eur J Cancer. 2018 Jan;89:49-55. doi: 10.1016/j.ejca.2017.10.034. Epub 2017 Dec 8.
2
MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis.MONITOR-GCSF DLBCL 子分析：用于预防化疗引起的发热性中性粒细胞减少症的生物类似物非格司亭的治疗模式/结局。
Eur J Haematol. 2018 Mar;100(3):241-246. doi: 10.1111/ejh.13002. Epub 2017 Dec 29.
3
The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and information.欧洲肿瘤内科学会（ESMO）关于肿瘤学中生物类似药的立场文件：加强提供准确的教育和信息。
ESMO Open. 2017 Aug 17;2(3):e000245. doi: 10.1136/esmoopen-2017-000245. eCollection 2017.
4
Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.生物类似药：欧洲医学肿瘤学会立场文件，特别涉及肿瘤学开方医生
ESMO Open. 2017 Jan 16;1(6):e000142. doi: 10.1136/esmoopen-2016-000142. eCollection 2016.
5
CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.CT-P6 对比曲妥珠单抗用于人表皮生长因子受体 2 阳性乳腺癌：一项随机、双盲、阳性对照、III 期等效性试验。
Lancet Oncol. 2017 Jul;18(7):917-928. doi: 10.1016/S1470-2045(17)30434-5. Epub 2017 Jun 4.
6
Interchangeability of Biosimilars: A European Perspective.生物类似药的可互换性：欧洲视角
BioDrugs. 2017 Apr;31(2):83-91. doi: 10.1007/s40259-017-0210-0.
7
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.拟用曲妥珠单抗生物类似药对比曲妥珠单抗治疗 ERBB2（HER2）阳性转移性乳腺癌患者的总缓解率：一项随机临床试验。
JAMA. 2017 Jan 3;317(1):37-47. doi: 10.1001/jama.2016.18305.
8
Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance.使用生物类似物粒细胞集落刺激因子动员健康供者造血干细胞：安全性、有效性及移植物性能
Transfusion. 2016 Dec;56(12):3055-3064. doi: 10.1111/trf.13853. Epub 2016 Sep 16.
9
Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF.使用生物类似物粒细胞集落刺激因子动员自体和异体外周血干细胞用于血液系统恶性肿瘤的移植
Vox Sang. 2016 Aug;111(2):178-86. doi: 10.1111/vox.12397. Epub 2016 Mar 8.
10
Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).使用生物类似药非格司亭预防化疗引起的（发热性）中性粒细胞减少症的治疗模式及结果（MONITOR-GCSF研究）
Support Care Cancer. 2016 Feb;24(2):911-925. doi: 10.1007/s00520-015-2861-z. Epub 2015 Aug 27.
Zotero 插件